STOCK TITAN

Synlogic (NASDAQ: SYBX) ends Nasdaq listing bid, plans OTC trading

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Synlogic, Inc. is voluntarily ending its effort to keep its common stock listed on The Nasdaq Capital Market after Nasdaq staff previously indicated they view the company as a “public shell.” The company withdrew its request for a Nasdaq hearings panel review, and Nasdaq has notified Synlogic that trading in its shares will be suspended at the open of business on January 21, 2026, with a Form 25 to follow to formally delist the stock. Synlogic expects its common stock to be quoted on the OTC Markets platform after delisting. The company states it will remain an SEC reporting company under the Securities Exchange Act of 1934 and that moving to OTC is not expected to affect its business operations, with further details on post-suspension trading to be disclosed when available.

Positive

  • None.

Negative

  • Nasdaq delisting and trading suspension: Synlogic is withdrawing its Nasdaq hearing request, and Nasdaq will suspend trading of its common stock on January 21, 2026, ahead of a planned Form 25 delisting filing.

Insights

Synlogic will move from Nasdaq to OTC trading after ending its listing appeal.

Synlogic chose to withdraw its request for a Nasdaq hearings panel review after staff previously indicated they believe the company is a “public shell.” This decision clears the way for Nasdaq to suspend trading and proceed with a Form 25 delisting, with suspension scheduled to begin at the open on January 21, 2026.

The company plans for its common stock to be quoted on OTC Markets after delisting and emphasizes that it will continue filing reports under the Securities Exchange Act of 1934. The disclosure states that the move to OTC is not expected to affect business operations, but trading dynamics and liquidity may differ from a national exchange listing.

Future disclosures are expected to outline the details of post-suspension trading. Investors who follow the stock will likely look to upcoming SEC reports, including the most recent Form 10-K and subsequent filings referenced in the risk discussion, for ongoing information about Synlogic’s strategy and status.

false000152759900015275992026-01-162026-01-16

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 16, 2026

 

 

SYNLOGIC, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37566

26-1824804

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

PO Box 30

 

Winchester, Massachusetts

 

01890

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 659-2802

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

SYBX

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on November 21, 2025, Synlogic, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that stated the Staff’s belief that the Company is a “public shell” and that, therefore, the continued listing of its securities is no longer warranted in the view of the Staff. In the Notice, the Staff explained that it based this belief on its review of the Company’s public disclosures and materials submitted to the Staff by the Company. The Notice further advised that, unless the Company timely requested a hearing before a Hearings Panel (the “Panel”), it would be subject to suspension/delisting on December 2, 2025. On November 28, 2025, the Company timely requested a hearing before the Panel, which temporarily stayed the suspension of trading and delisting of the Company’s common stock from Nasdaq. The hearing was scheduled for January 20, 2026.

After additional consideration, the Company has determined that it is no longer in its best interest to pursue continued listing of its common stock on The Nasdaq Capital Market and withdrew its request for a hearing on January 16, 2026. As a result, on January 16, 2026, the Company received notice from Nasdaq that its shares will be suspended at the open of business on January 21, 2026. Nasdaq is expected to file a Form 25 Notification of Delisting with the Securities Exchange Commission when all internal procedural periods have run.

The Company expects and plans for its shares of common stock to be quoted by the OTC Markets Group, Inc. (“OTC”) upon being delisted from Nasdaq.

The Company will continue to remain a reporting company under the Securities Exchange Act of 1934, as amended, and the transition to OTC is not expected to affect the Company’s business operations. The Company will make additional disclosures relating to post-suspension trading as that information becomes available.

 

 

Forward Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of federal and state securities laws. Such statements can be identified by words such as “will likely result,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “plan,” “project,” “outlook,” “should,” “could,” “may” or words of similar meaning and include, but are not limited to, statements regarding our future business and financial performance and prospects, including our expectations regarding the transactions described in this Current Report on Form 8-K. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results included in such forward-looking statements. Investors are cautioned not to place undue reliance on the forward-looking statements in this Current Report on Form 8-K, which information set forth herein speaks only as of the date hereof. The Company does not undertake, and it expressly disclaims, any intention or obligation to update any forward-looking statements made in this Current Report on Form 8-K, whether as a result of new information, future events or otherwise, except as required by law. A list and description of risks, uncertainties and other factors that could cause or contribute to differences in the Company’s results can be found in its filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent filings. The Company qualifies all of its forward-looking statements by these cautionary statements.

 

 

 

 

 

 

 

 

 

 

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 20, 2026

Synlogic, Inc.

 

 

 

By:

/s/ Mary Beth Dooley

 

 

Name:

Title:

Mary Beth Dooley
Principal Executive Officer and Principal Financial Officer

 

 


FAQ

Why is Synlogic (SYBX) being delisted from Nasdaq?

Nasdaq’s Listing Qualifications staff previously informed Synlogic that they believe the company is a “public shell” and that continued listing was not warranted. Synlogic then withdrew its request for a hearing before a Nasdaq panel, leading to a notice that its shares will be suspended and subsequently delisted via a Form 25 filing.

When will Synlogic (SYBX) shares stop trading on Nasdaq?

Synlogic received notice that its shares will be suspended at the open of business on January 21, 2026. After required internal procedures, Nasdaq is expected to file a Form 25 to formally delist the common stock.

Where will Synlogic stock trade after the Nasdaq delisting?

Synlogic states that it expects and plans for its common stock to be quoted by the OTC Markets Group, Inc. after it is delisted from The Nasdaq Capital Market, providing an alternative venue for trading.

Will Synlogic (SYBX) still file reports with the SEC after moving to OTC?

Yes. Synlogic discloses that it will continue to remain a reporting company under the Securities Exchange Act of 1934, as amended, meaning it will continue to file periodic reports with the SEC even after trading shifts to OTC Markets.

Does Synlogic expect the move to OTC to affect its business operations?

The company states that the transition to OTC is not expected to affect its business operations. The change primarily relates to the trading venue for its common stock, not to its underlying operational activities.

What additional information will Synlogic provide about trading after suspension?

Synlogic notes that it will make additional disclosures about post-suspension trading arrangements as that information becomes available, indicating that more detail will be provided in future communications or SEC filings.
Synlogic

NASDAQ:SYBX

SYBX Rankings

SYBX Latest News

SYBX Latest SEC Filings

SYBX Stock Data

13.10M
10.34M
11.26%
64.65%
0.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
WINCHESTER